[sci.med.aids] HICN404 News -- excerpts.

dmcanzi@watserv1.waterloo.edu (David Canzi) (03/08/91)

             Medical News for Week Feb. 18, 1991 to Feb. 28, 1991
        Copyright 1990: USA TODAY/Gannett National Information Network
                          Reproduced with Permission

                                      ---
                                 Feb. 19, 1991
                                      ---

                           RISK OF HIV-1 EVALUATED:

   The  results  of  a  6-year  study  indicated  that  the  risk   of   human
immunodeficiency  virus  type 1 transmission among health care workers appears
to depend on the kind of exposure.  The risk of HIV-1 transmission  with  skin
exposure  to  blood  from an infected patient is approximately 0.3 percent per
exposure.  The risk associated with mucous  membrane  cutaneous  exposures  is
smaller.

                         PUBLIC HOSPITALS OVERWHELMED:

   The nation's urban public hospitals  are  crumbling  under  the  strain  of
treating  AIDS,  drug  addictions,  gunshot  wounds  and  uninsured  patients,
according to a survey by the National Association of Public Hospitals.  Public
hospitals  lost  an  average of $40 million to care that was not reimbursed by
private insurance, Medicaid or Medicare.

                                      ---
                                 Feb. 20, 1991
                                      ---

                        HEARING FOCUSES ON INFECTIONS:

   The debate over what more should be done to protect patients  from  disease
will  reach its peak Thursday and Friday in Atlanta at a hearing called by the
federal Centers for Disease  Control.  A  decision  -  about  how  to  improve
infection  control and whether to require regular HIV antibody testing for all
health-care workers who risk blood-to-blood contact with patients will come in
weeks.

                         HBV POSES INFECTIOUS THREAT:

   The debate over how to prevent HIV infection  in  the  operating  room  and
dental office has focused new attention on another, more widespread infectious
threat,  the hepatitis B virus.  HBV infection spreads in all of the same ways
HIV does - sex,  needle-sharing and other blood-to-blood contact.  It leads to
chronic liver disease and causes several hundred deaths in the USA each year.

                           CDC RELEASES RISK FACTOR:

   According to CDC,  the risks of:  hepatitis B infection  from  an  infected
surgeon  - 2,400 in 1 million;  death from anesthesia - 100 in 1 million;  HIV
infection from a transfusion - 7 to 25 in 1 million;  death from penicillin  -
10 to 20 in 1 million;  and HIV infection from an infected surgeon - 2.4 to 24
in 1 million.

                                      ---
                                 Feb. 21, 1991
                                      ---

                        DRUG ENHANCES IMMUNE RESPONSE:

   A new drug that enhances immune responses in one rare disease shows promise
for more widespread use,  researchers say.  Injections of gamma interferon,  a
protein produced naturally in the body,  reduce infections in children with  a
type  of inherited immune deficiency,  says a report in Thursday's New England
Journal of Medicine. (For more, see special Disease package below.)

                          SPECIAL PACKAGE ON DISEASE:

                            DRUG HELPS INFECTIONS:

   Gamma interferon so far has not helped AIDS patients,  but  may  yet  prove
useful in preventing or treating some of their infections, says Dr. R. Alan B.
Ezekowitz of Harvard Medical School.  "We know it clearly works in one disease
but we are optimistic it will be useful in other diseases," says Dr.  John  I.
   Gallin, National Institute of Allergy and Infectious Diseases.

                         GENENTECH SEEKS FDA APPROVAL:

   New  research  has  prompted  the  FDA to approve sales of the drug made by
Genentech Inc.,  San Francisco.  The study included 128 children with  chronic
granulomatous  disease,  a  disorder in which immune system scavenger cells do
not produce chemicals needed to kill most fungi and  bacteria.  Patients  have
frequent,  sometimes  life-threatening infections,  and suffer from tumor-like
growths.

                          DRUG AFFECTS CHILDREN MORE:

    Gamma interferon is thought to improve production of the crucial  microbe-
killing  chemicals  and boost immunity in other ways.  Those who took the drug
had 70 percent fewer infections and spent less time  hospitalized  than  those
who  took placebos.  Results were most dramatic for children under age 10:  81
percent who took the drug had  no  severe  infections  for  a  year.  (End  of
package.)

                                      ---
                               Feb. 22-24, 1991
                                      ---

                        AIDS INFECTIONS OVERESTIMATED:

   Contracting the AIDS virus from an infected dentist  is  much  less  likely
than federal health officials have estimated,  the American Dental Association
says.  At worst, dentists may have infected seven patients in the past decade,
says  an  ADA  estimate  presented Thursday at a meeting called by the federal
Centers for Disease Control. (For more, see special AIDS package below.)

                           SPECIAL PACKAGE ON AIDS:

                             ADA REBUTS ESTIMATES:

   The  ADA  rebuttal  of  AIDS  infection estimates was among dozens of darts
thrown at a CDC draft report that estimated health professionals have infected
up to 100 dental patients and 28 surgical patients.  The dental  estimate  was
too  high,  says the ADA's Enid Neidle,  because officials wrongly assumed all
dental work poses some risk of blood-to-blood contact.

                       CDC ENCOURAGED NOT TO OVERREACT:

   Before CDC's meeting ends Friday,  CDC officials will have heard from  more
than 100 health policy experts, dentists, physicians and activists - virtually
all  of whom are urging the agency not to overreact to a small risk by forcing
all dentists and surgeons to take HIV tests and give up  their  work  if  they
test positive.

                                 CDC GUESSES:

   CDC  officials  concede  their  estimates  are  based  largely  on educated
guesswork.  Current guidelines focus on measures such as  use  of  gloves  and
masks and proper disposal of needles.  Proposed changes could come next month.
(End of package.)

                                      ---
                                 Feb. 26, 1991
                                      ---

                         INTERFERON GETS FDA APPROVAL:

   The Food and Drug Administration Monday approved the first treatment proven
to be effective  for  a  common  form  of  viral  hepatitis.  The  genetically
engineered drug, interferon alpha, will be used for non-A and non-B hepatitis,
which  affects  150,000  people  a year.  Interferon-A already is approved for
treating hairy cell leukemia, AIDS-related Kaposi's sarcoma and genital warts.

:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Volume  4, Number  4                                             March  3, 1991

              +------------------------------------------------+
              !                                                !
              !              Health Info-Com Network           !
              !                    Newsletter                  !
              +------------------------------------------------+
                         Editor: David Dodell, D.M.D.
                   St. Joseph's Hospital and Medical Center
    10250 North 92nd Street, Suite 210, Scottsdale, Arizona 85258-4599 USA
                          Telephone +1 (602) 860-1121
                              FAX +1 (602) 451-1165

   Copyright 1991 - Distribution on Commercial/Pay Systems Prohibited without
                              Prior Authorization

The Health Info-Com Network Newsletter is distributed weekly.  Articles  on  a
medical  nature  are  welcomed.  If  you  have an article,  please contact the
editor for information on how to submit it.  If you are interested in  joining
the automated distribution system, please contact the editor.

E-Mail Address:
                                    Editor:
                              FidoNet = 1:114/15
                           Bitnet = ATW1H @ ASUACAD
                     Internet = ddodell@stjhmc.fidonet.org
      LISTSERV = MEDNEWS @ ASUACAD.BITNET (or internet: asuvm.inre.asu.edu)
                         anonymous ftp = vm1.nodak.edu
       (Notification List/ftp = hicn-notify-request@stjhmc.fidonet.org)

Associate Editors:

o   Dr. Bruce MacDougall, University of Massachusetts at Amherst
       (Bitnet: BRUCEMA@UMASS)
o   Dr. J. Martin Wehlou (Bitnet: WEHLOU@BGERUG51)

-- 
David Canzi